Mihibin is reportedly the first FDA-approved liquid formulation of mycophenolic acid, an important immunosuppressant used to prevent organ rejection in transplant recipients.
FDA approves Azurity Pharmaceuticals’ Myhibin as an oral suspension for organ transplant recipients
Leave a Comment
